Paul Stoffels joined Galapagos as Chief Executive Officer in April 2022, and is an executive member and the Chairman of our Board of Directors since 26 April 2022. He also is a member of the Executive Committee at Galapagos. Prior to that, he was Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson where he set the company’s wide innovation agenda and led its pharmaceutical R&D-pipeline, as well as other external initiatives. Before that, he was worldwide Chairman of Pharmaceuticals of Johnson & Johnson which, under his leadership, significantly rejuvenated its product pipeline and adopted a transformational R&D-operating model, which resulted in the launch of 25 innovative medicines across the globe. Dr. Stoffels joined Johnson & Johnson in 2002, following the acquisition of Virco and Tibotec, where he was Chief Executive Officer and Chairman respectively, and where he led the development of several breakthrough products for the treatment of HIV. Dr. Stoffels also is a member of the Supervisory Board of Philips Healthcare in the Netherlands.
en.wikipedia.o...
#biotechnology #science #vc #startup #startups #startupideas #biology #biotech #chemistry #business #speech #speeches #investing #investment #lifescience #casestudy #scientist #scientists #inventors #inventor #inventions #invention #research #innovation #siliconvalley #entrepreneur #entrepreneurship #entrepreneurs #healthcare #genomics #genetics #history #biologia #technology #tech #founderstories #founder #founders #founderstory #scienceandtechnology #sciencestory #stories #bioengineering #engineering #engineer #biochemistry #discovery #discover #technical #health #education #educational #learning #learn #podcast #podcasts #podcasting #podcaster #technews
Axial Newsletter: axial.substack...
Build with Axial: build.axialvc....
linktr.ee/axia...
30 сен 2024
